Personalis Announces Expansion of Scientific and Clinical Team: Deanna Church and Robert Nussbaum

DNA

MENLO PARK, Calif.--(BUSINESS WIRE)--Personalis, Inc., the leading provider of advanced medical exome and genome sequencing and interpretation services today announced that Deanna Church, Ph.D., has joined its R&D team, and Robert Nussbaum, M.D., Professor of Medicine and Chief of the Division of Genomic Medicine at UCSF, has joined its Clinical and Scientific Advisory Board. Dr. Nussbaum will bring his deep expertise in medical genetics to guide development of Personalis' next-generation sequencing (NGS) based clinical services. Dr. Church comes to Personalis from the NCBI where she helped lead development of the newest Human Reference GRCh38 as well as genomic tools used by scientists worldwide. "We are thrilled that both Dr. Nussbaum and Dr. Church are joining our team," said Personalis Chief Scientific Officer Richard Chen, M.D. "Dr. Nussbaum brings world class expertise to our clinical product development while Dr. Church's deep expertise on the structure of the human genome, scientific tools and databases will help us continue to advance our application of NGS data to research and clinical use."

"We are dedicated to pushing the envelope of accuracy, completeness and clinical utility in human genomic analysis, and Drs. Church and Nussbaum both share our vision and will be instrumental in helping us to advance it"
"We are dedicated to pushing the envelope of accuracy, completeness and clinical utility in human genomic analysis, and Drs. Church and Nussbaum both share our vision and will be instrumental in helping us to advance it," added Personalis CEO John West.

About Personalis

Webinar

Digitize remote site monitoring with Box

Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing.

Personalis provides researchers and clinicians accurate DNA sequencing and interpretation of human exomes and genomes. We support researchers engaging in case-control, family-based, or proband-only genomic studies of disease, pharmacogenomics, and cancer. Our ACE (Accuracy and Content Enhanced) Technology™ supplements a standard exome or genome, substantially increasing its medically-relevant coverage and accuracy. Personalis builds on this enhanced sequencing foundation with innovative algorithms and proprietary databases for alignment, variant calling, annotation, and analysis. Through this comprehensive approach, we provide genomic data and interpretation of the highest accuracy.

Contacts

Personalis, Inc.
Carol Tillis, 1-650-752-1300
[email protected]
www.personalis.com

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.